|
Jul 31
|
These 2 “Strong Buy” Penny Stocks Are Poised for a Big Rally, Say Analysts
|
|
May 13
|
CorMedix Inc. (NASDAQ:CRMD) Q1 2024 Earnings Call Transcript
|
|
May 10
|
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
|
|
May 9
|
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 6
|
CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024
|
|
Apr 19
|
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
|
|
Apr 15
|
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)
|
|
Apr 11
|
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference
|
|
Apr 8
|
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
|
|
Apr 2
|
Breakeven On The Horizon For CorMedix Inc. (NASDAQ:CRMD)
|
|
Mar 27
|
CorMedix Inc. to Present at the Needham Annual Healthcare Conference
|
|
Mar 12
|
Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities for DefenCath
|
|
Mar 12
|
CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Mar 6
|
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
|
|
Dec 15
|
CorMedix Inc. Announces Appointment of Chief Legal Officer
|
|
Dec 4
|
CorMedix Inc. Announces Partnership With The Leapfrog Group
|
|
Nov 2
|
CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
|
|
Aug 30
|
CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath
|
|
Aug 10
|
Penn downgraded, Roblox upgraded: Wall Street's top analyst calls
|
|
Aug 8
|
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
|